BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Surprise phase III result bonks Intra-Cellular stock
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Surprise phase III result bonks Intra-Cellular stock
Sep. 30, 2016
By
Michael Fitzhugh
No Comments
An elevated placebo response matching the efficacy of experimental schizophrenia drug ITI-007 in a phase III trial sent shares of its developer, Intra-Cellular Therapies Inc., (NASDAQ:ITCI) down 63.6 percent to close at $15.42 on Thursday.
BioWorld